This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.
The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Tatyana Kushner, MD
Scientific Consultant/Advisor: Gilead, HDV, AbbVie, Eiger, GlaxoSmithKline, Madrigal, Ipsen, Mirum
Grant/Research Support: Icahn School of Medicine at Mount Sinai, Gilead
Harmeet Malhi, MBBS, FAASLD
Scientific Consultant/Advisor: Merck
Research Grants: LISCURE, NIH R01 NIH U01
Nancy Reau, MD, FAASLD
Scientific Consultant/Advisor: Intercept, Salix, CLDF/Focus Medical, ABIM, AbbVie, ACG, Gilead, VIR
Data Safety Monitoring Board: Arbutus
Leadership: AASLD
Anjana Pillai, MD, FAASLD
Scientific Consultant/Advisor: Replimune, Genentech, Exceles, Eisai, AstraZeneca, Boston Scientific, Commercial Speakers Bureau: Simply Speaking Hepatitis
Lisa VanWagner, MD, MS
Scientific Consultant/Advisor: Numares, NovoNordisk, Slingshot Insights, Madrigal, Gerson Lehrman Group, Alpha Insights
Research Grants: WL Gore & Associates, AstraZeneca